MicroRNA Detection in Cervical Exfoliated Cells as a Triage for Human Papillomavirus–Positive Women
Authors:
Open Access
- 4 September 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 106 (9)
Abstract
Papanicolaou (Pap) triage, with high specificity, has been recommended for primary Human papillomavirus (HPV) testing but is flawed by poor sensitivity and cytologist dependence. We evaluated the potential role of microRNA (miRNA) detection in cervical exfoliated cells in HPV-positive women from a clinic-based population. Primary HPV testing as well as Pap test were performed on all eligible women. Six miRNAs (miR-424/miR-375/miR-34a/miR-218/miR-92a/miR-93) were detected by RT-qPCR in cervical exfoliated cells. All HPV-positive women underwent colposcopy and further biopsy if indicated. Mann–Whitney U test, the receiver operating characteristic curve, logistic regression, and Pearson’s Chi-square were used to assess data. All tests of statistical significance were two-sided. A total of 1021 eligible HPV-positive women were enrolled. The expression of miR-424/miR-375/miR-34a/miR-218 in high-grade cervical intraepithelial neoplasia (CIN) and abnormal cytology was statistically significantly lower than that in low-grade CIN and normal cytology, respectively (all P < .05). Compared with the Pap test, both miR-424 and miR-375 detection achieved higher sensitivity (76.0% and 74.9% vs 63.8%, P < .05), higher negative predictive value (NPV) (85.7% and 85.4% vs 79.3%, P < .05), and comparable specificity while identifying CIN2 or worse (CIN2+). Similar results were achieved while identifying CIN3+. Multi-marker panels based on miR-424, miR-375, and miR-218 further improved the performance over any single miRNA test or Pap test. Single miR-424 or miR-375 detection and miR-424/miR-375/miR-218–based multimarker panels in cervical exfoliated cells show superior performance over Pap triage for high-grade CIN identification in a clinic-based population. Detection of miRNA may provide a new triage option for HPV-positive women.Keywords
This publication has 34 references indexed in Scilit:
- Salivary MicroRNAs as Promising Biomarkers for Detection of Esophageal CancerPLOS ONE, 2013
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trialThe Lancet Oncology, 2012
- miR-375 Is Down-Regulated in Squamous Cervical Cancer and Inhibits Cell Migration and Invasion via Targeting Transcription Factor SP1The American Journal of Pathology, 2011
- Upregulation of p18Ink4c expression by oncogenic HPV E6 via p53‐miR‐34a pathwayInternational Journal of Cancer, 2010
- Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trialThe Lancet Oncology, 2010
- HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trialThe Lancet Oncology, 2009
- p53‐repressed miRNAs are involved with E2F in a feed‐forward loop promoting proliferationMolecular Systems Biology, 2008
- 2006 consensus guidelines for the management of women with abnormal cervical cancer screening testsAmerican Journal of Obstetrics and Gynecology, 2007
- Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysisThe Lancet Infectious Diseases, 2007
- A microRNA component of the p53 tumour suppressor networkNature, 2007